BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25952786)

  • 1. Molecular targets in glioblastoma.
    Zorzan M; Giordan E; Redaelli M; Caretta A; Mucignat-Caretta C
    Future Oncol; 2015; 11(9):1407-20. PubMed ID: 25952786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
    Wardak Z; Choe KS
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SnapShot: glioblastoma multiforme.
    Kotliarova S; Fine HA
    Cancer Cell; 2012 May; 21(5):710-710.e1. PubMed ID: 22624719
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
    Bastien JI; McNeill KA; Fine HA
    Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
    Jagannathan J; Prevedello DM; Dumont AS; Laws ER
    Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies targeting glioblastoma stem cells.
    Carrasco-Garcia E; Sampron N; Aldaz P; Arrizabalaga O; Villanua J; Barrena C; Ruiz I; Arrazola M; Lawrie C; Matheu A
    Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):216-27. PubMed ID: 23607282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
    Reardon DA; Wen PY
    Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
    Mao H; Lebrun DG; Yang J; Zhu VF; Li M
    Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
    Gan HK; van den Bent M; Lassman AB; Reardon DA; Scott AM
    Nat Rev Clin Oncol; 2017 Nov; 14(11):695-707. PubMed ID: 28675164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.
    Gao Q; Lei T; Ye F
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1023-40. PubMed ID: 23731170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the molecular classification of glioblastoma to inform personalized treatment.
    Olar A; Aldape KD
    J Pathol; 2014 Jan; 232(2):165-77. PubMed ID: 24114756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
    Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
    Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular advances of brain tumors in radiation oncology.
    Noda SE; El-Jawahri A; Patel D; Lautenschlaeger T; Siedow M; Chakravarti A
    Semin Radiat Oncol; 2009 Jul; 19(3):171-8. PubMed ID: 19464632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA repair mechanisms and their clinical impact in glioblastoma.
    Erasimus H; Gobin M; Niclou S; Van Dyck E
    Mutat Res Rev Mutat Res; 2016; 769():19-35. PubMed ID: 27543314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targeted therapy of glioblastoma.
    Le Rhun E; Preusser M; Roth P; Reardon DA; van den Bent M; Wen P; Reifenberger G; Weller M
    Cancer Treat Rev; 2019 Nov; 80():101896. PubMed ID: 31541850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward precision medicine in glioblastoma: the promise and the challenges.
    Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
    Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma multiforme: Pathogenesis and treatment.
    Alifieris C; Trafalis DT
    Pharmacol Ther; 2015 Aug; 152():63-82. PubMed ID: 25944528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma targeted therapy: updated approaches from recent biological insights.
    Touat M; Idbaih A; Sanson M; Ligon KL
    Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrachromosomal DNA: Redefining the pathogenesis of glioblastoma.
    Shiras A; Mondal A
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188551. PubMed ID: 33892052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of molecular profiling on clinical trial design for glioblastoma.
    Chakravarti A; Tyndall E; Palanichamy K; Mehta M; Aldape K; Loeffler J
    Curr Oncol Rep; 2007 Jan; 9(1):71-9. PubMed ID: 17164051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.